Cargando…

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer

OBJECTIVE: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) can provide prognostic information, especially 18F-FDG uptake has been proven to be a predictor for the prognosis of various tumors. Nevertheless, the prognosis of other PET parameters in the metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi, Liu, Cheng, Wang, Bibo, Hu, Xichun, Gong, Chengcheng, Zhao, Yannan, Xie, Yizhao, Zhang, Yingjian, Song, Shaoli, Yang, Zhongyi, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123971/
https://www.ncbi.nlm.nih.gov/pubmed/34007206
http://dx.doi.org/10.2147/IJGM.S293998
_version_ 1783693073342005248
author Li, Yi
Liu, Cheng
Wang, Bibo
Hu, Xichun
Gong, Chengcheng
Zhao, Yannan
Xie, Yizhao
Zhang, Yingjian
Song, Shaoli
Yang, Zhongyi
Wang, Biyun
author_facet Li, Yi
Liu, Cheng
Wang, Bibo
Hu, Xichun
Gong, Chengcheng
Zhao, Yannan
Xie, Yizhao
Zhang, Yingjian
Song, Shaoli
Yang, Zhongyi
Wang, Biyun
author_sort Li, Yi
collection PubMed
description OBJECTIVE: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) can provide prognostic information, especially 18F-FDG uptake has been proven to be a predictor for the prognosis of various tumors. Nevertheless, the prognosis of other PET parameters in the metastatic setting remains unclear. This study was aimed at investigating pretreatment parameters based on 18F-FDG-PET/CT so as to estimate the progression-free survival (PFS) of metastatic breast cancer (MBC) patients receiving first-line treatment. METHODS: MBC patients who underwent a whole-body 18F-FDG-PET/CT prior to first-line therapy were enrolled. The heterogeneity parameter of PET/CT was analyzed, including heterogeneity index (HI) and general parameters (metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax) and mean SUV (SUVmean). PFS was used to evaluate the treatment outcome. Kaplan–Meier method was adopted to carry out survival analysis and Log rank test was conducted to make a comparison. RESULTS: A total of 177 MBC patients were selected, in which 68 were in De novo stage IV. Thirty patients were human epidermal growth factor receptor 2 (HER2)-positive, 60 patients were triple-negative, and 87 patients were hormone receptor (HR)-positive and HER2-negative. In the whole population, patients with high baseline SUVmax, SUVmean, MTV, TLG or HI were associated with lower PFS (P=0.028, 0.005, 0.017, 0.026 and 0.035, respectively). Among the patients in De novo stage IV, those with high HI at baseline had significantly shorter PFS (P=0.001). In HR+/HER2- and HER2+ subgroups, only baseline HI showed the predictive value of PFS (P=0.023 and 0.049, respectively). In the triple-negative subgroup, high baseline SUVmax, MTV or TLG showed the predictive value of worse PFS (P=0.030, 0.011 and 0.023, respectively). CONCLUSION: Pretreatment 18F-FDG-PET/CT parameters show the predictive value of PFS in MBC patients receiving first-line treatment. However, predictive PET/CT parameters might be different in patients with different molecular subtypes and De novo stage IV.
format Online
Article
Text
id pubmed-8123971
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81239712021-05-17 Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer Li, Yi Liu, Cheng Wang, Bibo Hu, Xichun Gong, Chengcheng Zhao, Yannan Xie, Yizhao Zhang, Yingjian Song, Shaoli Yang, Zhongyi Wang, Biyun Int J Gen Med Original Research OBJECTIVE: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) can provide prognostic information, especially 18F-FDG uptake has been proven to be a predictor for the prognosis of various tumors. Nevertheless, the prognosis of other PET parameters in the metastatic setting remains unclear. This study was aimed at investigating pretreatment parameters based on 18F-FDG-PET/CT so as to estimate the progression-free survival (PFS) of metastatic breast cancer (MBC) patients receiving first-line treatment. METHODS: MBC patients who underwent a whole-body 18F-FDG-PET/CT prior to first-line therapy were enrolled. The heterogeneity parameter of PET/CT was analyzed, including heterogeneity index (HI) and general parameters (metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax) and mean SUV (SUVmean). PFS was used to evaluate the treatment outcome. Kaplan–Meier method was adopted to carry out survival analysis and Log rank test was conducted to make a comparison. RESULTS: A total of 177 MBC patients were selected, in which 68 were in De novo stage IV. Thirty patients were human epidermal growth factor receptor 2 (HER2)-positive, 60 patients were triple-negative, and 87 patients were hormone receptor (HR)-positive and HER2-negative. In the whole population, patients with high baseline SUVmax, SUVmean, MTV, TLG or HI were associated with lower PFS (P=0.028, 0.005, 0.017, 0.026 and 0.035, respectively). Among the patients in De novo stage IV, those with high HI at baseline had significantly shorter PFS (P=0.001). In HR+/HER2- and HER2+ subgroups, only baseline HI showed the predictive value of PFS (P=0.023 and 0.049, respectively). In the triple-negative subgroup, high baseline SUVmax, MTV or TLG showed the predictive value of worse PFS (P=0.030, 0.011 and 0.023, respectively). CONCLUSION: Pretreatment 18F-FDG-PET/CT parameters show the predictive value of PFS in MBC patients receiving first-line treatment. However, predictive PET/CT parameters might be different in patients with different molecular subtypes and De novo stage IV. Dove 2021-05-11 /pmc/articles/PMC8123971/ /pubmed/34007206 http://dx.doi.org/10.2147/IJGM.S293998 Text en © 2021 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Yi
Liu, Cheng
Wang, Bibo
Hu, Xichun
Gong, Chengcheng
Zhao, Yannan
Xie, Yizhao
Zhang, Yingjian
Song, Shaoli
Yang, Zhongyi
Wang, Biyun
Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
title Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
title_full Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
title_fullStr Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
title_full_unstemmed Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
title_short Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
title_sort prediction of pretreatment 18f-fdg-pet/ct parameters on the outcome of first-line therapy in patients with metastatic breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123971/
https://www.ncbi.nlm.nih.gov/pubmed/34007206
http://dx.doi.org/10.2147/IJGM.S293998
work_keys_str_mv AT liyi predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT liucheng predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT wangbibo predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT huxichun predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT gongchengcheng predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT zhaoyannan predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT xieyizhao predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT zhangyingjian predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT songshaoli predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT yangzhongyi predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer
AT wangbiyun predictionofpretreatment18ffdgpetctparametersontheoutcomeoffirstlinetherapyinpatientswithmetastaticbreastcancer